: FDA approves Reata’s rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments

The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc.’s treatment for Friedreich’s ataxia, a rare inherited disease that causes damage to the nervous system. Reata’s RETA stock was halted in after-hours trading on Tuesday in advance of the FDA’s decision. The drug, omaveloxolone, which is now called Skyclarys,…

Article Attribution | Read More at Article Source